Top View
- “CRE Mechanisms and Their Importance for Infection Prevention ” Paul C
- Antimicrobial Activity of Doripenem (S-4661): a Global Surveillance Report (2003) T
- Management of Extended-Spectrum Beta-Lactamase-Positive Gram-Negative Bacterial Urologic Infections
- Spectrophotometric Determination of Doripenem, Ertapenem in Bulk and Injection Formulations by F-C Reagent
- Teflaro Generic Name: Ceftaroline Fosamil Manufacturer
- Optimization of Polymyxin B in Combination with Doripenem to Combat Mutator Pseudomonas Aeruginosa
- The Treatment of Melioidosis
- Penicillin Allergy Cross-‐Reactivity • Roughly 10% of the Population
- PK-PD Evaluation of Doripenem (DOR) Against Extended Spectrum ß-Lactamase (ESBL) Producing Enterobacteraceae D
- Antibiotic Considerations in the Treatment of Multidrug-Resistant (MDR) Pathogens: a Case-Based Review
- Antibiotic Sensitivity FINAL V4.Xlsx
- Successful Use of Repurposed Drugs for MDR TB: Meropenem/Clavulanate and Its Newer Rela Ves
- DDDT-3083-Characteristics of Doripenem: a New Broad-Spectrum
- CARBAPENEM RESISTANCE from Diagnosis to Outbreak Management TABLE of CONTENTS INTRODUCTION
- Elizabeth T. Escaño-Gallardo, MD, FPPS, FPIDSP 23Rd Annual Convention Pediatric Infectious Disease Society of the Philippines February 19, 2016 Objectives
- Doribax, INN-Doripenem
- DORIBAX, INN: Doripenem Monohydrate
- Antimicrobial Resistance Surveillance of Doripenem in China
- Evaluation of Polymyxin B-Based and Dual- Carbapenem Combinations Against Carbapenem-Resistant Enterobacteriaceae Co- Harbouring Mcr-1 and KPC-2
- Antimicrobial Activity of Broad-Spectrum Β-Lactams, Including Doripenem, Tested Against Bloodstream Infection Isolates
- Therapeutic Drug Monitoring of Continuous Infusion Doripenem in a Pediatric Patient on Continuous Renal Replacement Therapy Jeffrey J
- Double Anaerobic Coverage: What Is the Role in Clinical Practice?
- Variations and Trends in the Activity of Doripenem and Other Broad-Spectrum Agents Against Leading
- In Vitro and in Vivo Efficacy Study of Cefepime, Doripenem, Tigecycline, and Tetracycline Against Extended-Spectrum Beta-Lactamases Escherichia Coli in Chickens
- Proposed Modifications to EUCAST Clinical Breakpoints
- Pharmacokinetics and Tissue Penetration of a New Carbapenem, Doripenem, Intravenously Administered to Laboratory Animals*
- Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant Pseudomonas Aeruginosa and Minimize Biofilm Formation
- Case Report Polymyxin Combination Therapy and the Use of Serum
- Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella Pneumoniae
- Antibiotics in the Clinical Pipeline in 2013
- Assessment of Doripenem, Meropenem, and Imipenem Against Respiratory Isolates of Pseudomonas Aeroginosa in a Tertiary Care Hospital of North India